NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of…
ATLANTA, July 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Macrogenics, Inc.…
SAN FRANCISCO, July 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered…
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered…
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to…
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
MGNX Investors with Substantial Losses Encouraged to Contact Hagens Berman MGNX Investors with Substantial Losses Encouraged to Contact Hagens Berman…
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
MGNX Investors with Substantial Losses Encouraged to Contact Hagens Berman MGNX Investors with Substantial Losses Encouraged to Contact Hagens Berman…
MacroGenics’ safety woes have followed it into phase 2. | MacroGenics’ safety woes have followed it into phase 2. Having…
MGNX earnings call for the period ending March 31, 2024.…
…
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
MacroGenics stock target lifted to $29 on ASCO optimism…
MGNX earnings call for the period ending December 31, 2023.…
…
BTIG raies MacroGenics stock on cancer drug potential…
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
ROCKVILLE, MD, Feb. 02, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing…
ROCKVILLE, MD, Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
…
MacroGenics gains as Citi upgrades to Buy…
MGNX earnings call for the period ending September 30, 2023.…
…
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,…
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
The company announced second-quarter earnings....…
MGNX earnings call for the period ending June 30, 2023....…
MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,…
MGNX earnings call for the period ending March 31, 2023....…
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…
MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…
ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Incyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenics...…
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing…
Latest Ratings for MGNX
DateFirmActionFromTo Feb 2022CitigroupUpgradesNeutralBuy Feb 2022SVB LeerinkMaintainsOutperform Feb 2022BMO CapitalInitiates Coverage OnOutperform
…
The company had quite a comedown shortly after releasing its latest set of annual results....…
The cancer-focused biotech delivered a strong earnings report....…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MGNX earnings call for the period ending December 31, 2022....…